SEOVF — SERNOVA CORP.
—
OTC ·
Unknown ·
Unknown ·
CIK 1491434 ·
Last close
$0.08
Market Cap
$30.21M
52W High
$0.14
52W Low
$0.07
ADV30
50,777
Next earnings
2026-09-10
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Apr 2026 | 0 | — | -2,296,593 | -3,228,053 | 1,534,189 | 1,053,157 | 11,173,701 |
| Jan 2026 | 0 | — | -2,115,020 | -2,334,402 | 1,012,821 | 576,221 | 26,614,968 |
| Oct 2025 | 0 | — | -2,396,204 | -2,197,203 | 764,234 | 265,004 | 25,841,064 |
| Jul 2025 | 0 | — | -3,499,897 | -4,073,783 | 910,719 | 83,617 | 25,343,166 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-5,498,094
Investing CF
$24,958
Financing CF
$4,528,586
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.04
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-171,665,063
Inventory
—
Receivables
$116,838
ST Investments
—
EBIT TTM
$-10,260,116
Pretax Income TTM
$-11,939,287
Interest Exp TTM
$1,679,171
Analysts
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Oct 2025 | 0 | -15,023,024 | -15,743,466 | 764,234 | 25,841,064 | — | -10,907,967 |
| Oct 2024 | 0 | -31,663,742 | -32,192,135 | 7,527,339 | 20,483,947 | — | -18,896,313 |
| Oct 2023 | 0 | -40,501,593 | -38,997,520 | 22,106,815 | 9,592,280 | — | -30,339,117 |
| Oct 2022 | 0 | -24,753,761 | -24,420,536 | 52,484,921 | 4,876,256 | — | -14,421,398 |
| Oct 2021 | — | — | — | — | — | — | — |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| IEGCF | Independence Gold Corp. | $30.21M | $0.11 | — |
| DAIO | DATA I/O CORP | $29.94M | $2.88 | — |
| CLIR | ClearSign Technologies Corp | $30.53M | $4.84 | — |
| ATCMF | ATICO MINING Corp | $29.61M | $0.16 | — |
| TTIPF | Thiogenesis Therapeutics, Corp. | $29.39M | $0.42 | — |
News headlines (Yahoo Finance, 1h cache)
A Diabetes Therapy Just Locked In Its Cell Supplier, and the Race to End Insulin Injections Is Heating Up
2026-07-21 13:00 · Yahoo
Sernova Biotherapeutics Receives FDA Orphan Drug Designation for Autologous Islet Transplantation for Prevention of Diabetes Due to Total Pancreatectomy
2026-06-17 11:00 · Yahoo
Sernova Biotherapeutics Announces Closing of Recently Approved Financings
2026-04-23 20:15 · Yahoo
Sernova Biotherapeutics Announces Affirmative Voting Results from 2026 Annual General Meeting of Shareholders
2026-04-09 11:00 · Yahoo
Sernova Biotherapeutics Announces Close of Non-Brokered Private Placement Financing
2026-03-24 11:00 · Yahoo
Sernova Biotherapeutics Strengthens Balance Sheet with $7.1 Million in Financings Plus Net Retirement of a Cumulative $17 Million of Debt Subject to Shareholder Approval
2026-03-04 12:00 · Yahoo
Sernova Biotherapeutics Announces Warrant Amendments
2026-02-20 12:00 · Yahoo
Sernova Biotherapeutics Closes First Tranche of a Private Placement of Equity Financing to Support Ongoing Clinical Efforts
2025-11-13 12:00 · Yahoo
Sernova Biotherapeutics Announces $13 Million Debt-to-Equity Conversion Eliminating Significant Financing Overhang
2025-10-01 11:00 · Yahoo
Loss-Making Sernova Biotherapeutics Inc (TSE:SVA) Expected To Breakeven In The Medium-Term
2025-08-30 13:49 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.